SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-326031
Filing Date
2021-11-10
Accepted
2021-11-10 16:20:03
Documents
14
Period of Report
2021-11-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d200650d8k.htm   iXBRL 8-K 23937
2 EX-99.1 d200650dex991.htm EX-99.1 65236
6 GRAPHIC g200650g57l90.jpg GRAPHIC 7110
  Complete submission text file 0001193125-21-326031.txt   233901

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA sbtx-20211110.xsd EX-101.SCH 2892
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE sbtx-20211110_lab.xml EX-101.LAB 18888
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE sbtx-20211110_pre.xml EX-101.PRE 11860
7 EXTRACTED XBRL INSTANCE DOCUMENT d200650d8k_htm.xml XML 3480
Mailing Address 500 FAIRVIEW AVENUE NORTH, SUITE 600 SEATTLE WA 98109
Business Address 500 FAIRVIEW AVENUE NORTH, SUITE 600 SEATTLE WA 98109 206-456-2900
Silverback Therapeutics, Inc. (Filer) CIK: 0001671858 (see all company filings)

IRS No.: 811489190 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39756 | Film No.: 211396953
SIC: 2834 Pharmaceutical Preparations